PHARMACY

U.S. Type 2 diabetes market to more than double by 2019

BY Alaric DeArment

NEW YORK — The global market for Type 2 diabetes will nearly double over the next six years, according to a new report.

GBI Research announced the release of a study Tuesday indicating that the market will grow from 2012’s $20.4 billion to $38.8 billion by 2019, at an annual growth rate of 10.2%. The United States’ market, meanwhile, will more than double, from $12.7 billion last year to $27.2 billion in 2019.

"The strong forecast for the Type 2 diabetes market is reliant upon the ability of late-stage pipeline drugs, such as gemigliptin, to reach expectations created by promising clinical trial results, and of newly marketed products, including [Takeda’s] Nesina and [Boehringer Ingelheim and Eli Lilly’s] Tradjenta, to capture significant share of the market," GBI analyst Dominic Trewartha said. Gemigliptin is the chemical name of Korea-based LG Life Sciences’ Zemiglo, currently approved in South Korea.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves new dosage strength for Purdue Pharma’s Butrans

BY Alaric DeArment

STAMFORD, Conn. — The Food and Drug Administration has approved a new dosage strength for a chronic pain patch made by Purdue Pharma, the drug maker said Tuesday.

Purdue announced the approval of the 15-microgram-per-hour strength of Butrans (buprenorphine). The drug is used to treat moderate to severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. The new strength is in addition to the 5-microgram, 10-microgram and 20-microgram strengths already on the market, and it will be launched next month.

"The new strength provides another option when adjusting the dose to obtain an appropriate balance between adequate pain relief and opioid-related adverse reactions," Purdue SVP research and development Gary Stiles said.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AbbVie, Ablynx sign deal for investigative autoimmune drug

BY Alaric DeArment

GHENT, Belgium — Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million, the companies said.

The two drug makers announced that AbbVie would license the drug ALX-0061 for an upfront payment of $175 million plus milestone payments worth up to $665 million, as well as royalties. The drug belongs to a class known as anti-interleukin-6R nanobodies, which work by targeting an immune-system protein pathway that plays a key role in the inflammation associated with RA.

Under the deal, Ablynx will complete the mid-stage clinical trials of the drug currently underway in patients with RA and systemic lupus erythematosus. After fulfilling pre-defined success criteria, AbbVie will in-license the drug and be responsible for late-stage development and commercialization, while Abblynx will have an option for co-promotion in Belgium, the Netherlands and Luxembourg.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?